echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > In the past week, institutions have intensively investigated a number of listed pharmaceutical companies

    In the past week, institutions have intensively investigated a number of listed pharmaceutical companies

    • Last Update: 2022-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
     Wind data shows that in the past week, institutions have intensively investigated a number of listed pharmaceutical companies
    .
    Among them, Yan'an Bikang was favored by institutions and received a total of 143 institution surveys, Teyi Pharmaceutical obtained 59 institution investigations, and Xinhua Pharmaceutical received 25 institution investigations

    .
    On December 27, Yan’an Bikang released a record of investor relations activities.
    The company accepted investigations from 143 institutions on December 27, 2021.
    The types of institutions were insurance companies, others, fund companies, securities companies, and Sunshine private equity institutions

    .
    According to the data, the main business of the legal person of Yanan Bikang Pharmaceutical Co.
    , Ltd.
    is the pharmaceutical industry sector, the pharmaceutical business sector, the new energy and new materials sector, and the pharmaceutical intermediates (pharmaceutical intermediates, pesticide intermediates) sector

    .
    The company's main products are digestive system drugs, urinary system drugs, pediatric drugs, tonic drugs, rheumatoid bone disease drugs, heat-clearing and detoxifying and upper respiratory tract drugs, iron supplement drugs, lithium hexafluorophosphate, high-strength high-modulus polyethylene fiber, sodium triclopyridine, 5.
    5 -Dimethylhydantoin, benzaldehyde

    .
    In the pharmaceutical industry, the company owns many brands such as Bikang Weizheng, Baoshi Baobao, Xinrong, E Jie and so on

    .
    In response to investors’ questions, Yan’an Bikang stated that the company’s pharmaceutical intermediates product has a production capacity of 15,000 tons/year of sodium triclopyridate and a 5,5-dimethylhydantoin production capacity of 8,000 tons/year, which is a large-scale production capacity

    .
    It is understood that on December 29, Yan'an Bikang opened at 12.
    22 yuan.
    As of 10:10, the stock rose 9.
    99% to 13.
    43 yuan, and the price limit was closed

    .
    On December 26, Teyi Pharmaceutical issued an announcement stating that it had accepted a total of 59 investigations

    .
    According to data, Teyi Pharmaceutical is mainly engaged in the research and development, production and sales of Chinese patent medicines and chemical preparations

    .
    According to the data, the 2021 third quarter report of Teyi Pharmaceuticals shows that the company's main operating income increased by 21.
    33% year-on-year to 525 million yuan; net profit attributable to the parent increased by 257.
    54% year-on-year to 103 million yuan; non-net profit increased by 255.
    09% year-on-year to 89,428,500 yuan

    .
    In response to investors’ questions, Teyi Pharmaceutical said that Zhikebao Tablets are currently the company’s key product and also the company's core product.
    In the company's income structure, Zhikebao Tablets account for about 35% of the company's revenue

    .
    At present, Zhikebao tablets have a dedicated production workshop.
    The current production capacity is 1 billion tablets (about 40 million boxes).
    In the future, production equipment can be added to existing sites according to market needs.
    The production capacity can reach 2.
    4 billion tablets (about 100 million boxes).
    ), it is estimated that in 5-8 years, the annual sales volume of Zhikebao tablets will reach 2.
    4 billion tablets

    .
    Teyi Pharmaceutical will closely follow the general trend of national reform and development and focus on the development of proprietary Chinese medicines

    .
    The company has cultivated Dermatopathy Xuedu Pills and Jiangtangshu Pills as major varieties following Zhikebao Tablets.
    At present, the company has initiated clinical trials of Dermatopathy Xuedu Pills, and the company will pass the core varieties of clinical research and real-world research.
    , To promote the growth of the company's characteristic traditional Chinese medicine varieties into a large variety of traditional Chinese medicines, and to enhance the company's operating performance

    .
    Teyi Pharmaceutical hopes that through 3 to 5 years of hard work, the dermatosis blood poison pill and Jiangtang Shu pill will become the core product of traditional Chinese medicine with an annual marketing revenue of about 300 million

    .
    Xinhua Pharmaceutical released a record sheet of investor relations activities on December 28, stating that the company accepted investigations from 25 institutions on December 23, 2021.
    The types of institutions were insurance companies, others, fund companies, securities companies, and Sunshine private equity institutions

    .
    According to data, Xinhua Pharmaceutical is mainly engaged in the development, manufacturing and sales of chemical raw materials, preparations, chemicals and other products; the company’s main products include antipyretic and analgesic raw materials, tablets, injections, capsules, and pharmaceutical intermediates

    .
    In response to investors’ questions on “Domestic preparations’ sales strategy? How does the company respond to centralized procurement?” Xinhua Pharmaceutical said, 1.
    The company is actively promoting the strategic development plan for large preparations.
    Domestic preparations are sold through market segmentation and regional management.
    Has a sales team of nearly 1,000 people; 2.
    Actively participate in bidding and procurement, and through targeted bidding, the company has won the bid for 6 varieties and 8 specifications, and product sales have increased significantly, such as the sales of glimepiride, cefradine, etc.
    The volume has risen sharply; 3.
    Select strategic varieties, formulate special implementation plans, and actively cultivate.
    For example, the self-produced raw material variety Jiening is expected to have sales of about 80 million yuan this year, an increase of 17% year-on-year, and rabeprazole sodium exceeds 200 million yuan.
    Yuan, both hit a record high; 4.
    Continue to promote quality generic drugs, give full play to the advantages of the API industry chain, enhance brand effect, and increase product market share

    .
    In addition to the above-mentioned companies, companies such as East China Pharmaceutical, Tonghe Pharmaceutical, Xianju Pharmaceutical, Xinhua Pharmaceutical, and Jiudian Pharmaceutical have also welcomed a number of investigations

    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.